Compare SBSW & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SBSW | ABVX |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | South Africa | France |
| Employees | N/A | N/A |
| Industry | Precious Metals | |
| Sector | Basic Materials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 9.6B |
| IPO Year | N/A | N/A |
| Metric | SBSW | ABVX |
|---|---|---|
| Price | $13.19 | $126.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | $6.90 | ★ $112.83 |
| AVG Volume (30 Days) | ★ 4.8M | 1.7M |
| Earning Date | 08-28-2025 | 08-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,290,132,787.00 | $7,073,400.00 |
| Revenue This Year | $14.61 | $6.80 |
| Revenue Next Year | $15.74 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 3.11 | N/A |
| 52 Week Low | $3.05 | $4.77 |
| 52 Week High | $13.40 | $138.49 |
| Indicator | SBSW | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 64.47 | 61.02 |
| Support Level | $12.10 | $124.98 |
| Resistance Level | $12.81 | $138.49 |
| Average True Range (ATR) | 0.52 | 6.98 |
| MACD | 0.05 | 0.25 |
| Stochastic Oscillator | 66.67 | 61.44 |
Sibanye Stillwater Ltd is a South African mining and metals processing group with a diverse portfolio of operations, projects, and investments across five continents. The Group is also one of the foremost recyclers of PGM autocatalysts and has interests in mine tailings retreatment operations. It is a producer of platinum, palladium, and rhodium and is a top-tier gold producer. It also produces and refines iridium and ruthenium, nickel, chrome, copper, and cobalt. Its products are Gold, Nickel, Zinc, Chrome, PGMs, and other.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.